GlassScriptPhysician profile
Emily Breidbart
NPI 1710291661
$17,818.33
in general payments reported to CMS, 2019-2025
10 companies · $9,651 in 2025
The $9,651 reported for 2025 was more than what 89% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.27 · 2022: $1,298 · 2023: $369 · 2024: $6,468 · 2025: $9,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $12K · Consulting Fee: $3,080 · Food and Beverage: $1,419 · Travel and Lodging: $418 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $11,538.00 |
| Consulting Fee | $3,080.00 |
| Food and Beverage | $1,419.40 |
| Travel and Lodging | $418.39 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biomarin Pharmaceutical INC. | $12,640.47 | 2022-2025 | Voxzogo 1.2mg |
| Alexion Pharmaceuticals, INC. | $2,459.26 | 2022-2024 | Strensiq |
| Pfizer INC. | $2,029.96 | 2024-2025 | |
| Novo Nordisk INC | $222.69 | 2021-2024 | Wegovy, Sogroya |
| Neurocrine Biosciences, INC. | $172.81 | 2025 | |
| Tolmar, INC. | $114.86 | 2025 | Fensolvi |
| Sanofi-Aventis U.S. LLC | $100.22 | 2024 | |
| Ascendis Pharma Endocrinology INC | $52.53 | 2025 | Yorvipath |
| Cequr Corporation | $25.53 | 2025 | Cequr Simplicity |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Breidbart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.